Direkt zum Inhalt
Merck

[Takotsubo cardiomyopathy: a novel beta-adrenergic blocker withdrawal syndrome].

Orvosi hetilap (2013-02-12)
János Tomcsányi, Kinga Jávor, Hrisula Arabadzisz, András Zsoldos, Vince Wagner, Balázs Sármán
ZUSAMMENFASSUNG

The authors describe two cases of takotsubo cardiomyopathy developing after an abrupt withdrawal of carvedilol and bisoprolol. Takotsubo or stress cardiomyopathy is characterized by acute and reversible cardiac dysfunction without coronary artery disease. It is triggered by acute emotional or physical stress, drugs or drug withdrawal. The immediate discontinuation of the long acting vasodilator beta-blocker, carvedilol has not yet been described to cause takotsubo cardiomyopathy. The authors recommend cautious withdrawal of beta-blockers.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Bisoprolol -hemifumarat (Salz), ≥98% (HPLC), solid
Bisoprololfumarat, European Pharmacopoeia (EP) Reference Standard
Bisoprolol für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Bisoprolol für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard